Reaction
Hepatosplenic T-Cell Lymphoma reporting signals
As of the last recalculation, Hepatosplenic T-Cell Lymphoma appears in 368 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is MERCAPTOPURINE (PRR 286.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Mercaptopurine | 71 | 286.7 | 287.9 |
| Anakinra | 48 | 188.1 | 188.6 |
| Azathioprine | 155 | 171.2 | 171.5 |
| Infliximab | 184 | 94.3 | 94.4 |
| Thalidomide | 44 | 76.9 | 76.9 |
| Etoposide | 64 | 59.4 | 59.4 |
| Adalimumab-Fkjp | 38 | 51.6 | 51.7 |
| Adalimumab-Aaty | 38 | 50.5 | 50.6 |
| Adalimumab-Adaz | 41 | 49.3 | 49.4 |
| Ifosfamide | 17 | 46.9 | 46.9 |
| Mesalamine | 38 | 42.6 | 42.6 |